Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,328.00
Bid: 12,346.00
Ask: 12,348.00
Change: -228.00 (-1.82%)
Spread: 2.00 (0.016%)
Open: 12,512.00
High: 12,554.00
Low: 12,328.00
Prev. Close: 12,556.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-A medium term view on the U.S. dollar

Wed, 17th Mar 2021 12:48

* European Stoxx 600 down 0.5%

* Autos stock index best performer, up 1.8%

* BMW shares jump after strong 2021 forecast

* Verbund shares fall after results

March 17 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

A MEDIUM-TERM VIEW ON THE U.S. DOLLAR (1244 GMT)

The dollar is holding steady ahead of today’s Fed policy
meeting outcome after rising recently as a fresh spike in
Treasury yields re-ignited inflation fears and sparked a
sell-off in riskier currencies.

But this kind of relationship might change, if we take a
broader angle.

A Fed on hold well into 2023 is likely to see greater
pressure on the dollar on “deteriorating external account and
negative real yields,” according to Deutsche Bank, which sees
EUR/USD “rising and exceeding medium-term measures of purchasing
power parity of around 1.25.”

A new framework adopted by the central bank last year means
it will allow inflation to rise above its target for a period to
make inflation average 2% over time.

“Rising back-end yields and a weaker dollar are entirely
consistent with historical experience: the correlation between
the two has in the past been close to zero, and what matters
most for the dollar is front-end real yields,” according to
Deutsche Bank analysts.

A central bank that endorses a controlled overshoot of
inflation, as the Fed is supposed to do for a foreseeable
future, “is likely to do significant damage to the dollar.”

With U.S. fiscal stimulus targeting low income households
with high marginal propensity to consume, rising domestic demand
is expected to widen the current account deficit.

In the chart below the euro dollar rate (green)
recently falling as U.S. yields (orange) rise.

(Stefano Rebaudo)

*****

ESG FLOWS HYPE, BUT PERFORMANCE SLOWS (1152 GMT)

Flows into ESG strategies continue to gather momentum.

In the first two months of the year, $16.7 billion went into
long-term retail funds in the U.S. and $99.7 billion into non-US
funds, according to figures from Jefferies.

"In addition to positive flow momentum, new product launches
with ESG designations also continue to flourish," the analysts
add.

March marked a milestone for sustainable finance in Europe,
they add, with the launch of the Sustainable Finance Disclosure
Regulation (SFDR).

"It is designed to curb "greenwashing" throughout the entire
investment value chain (asset managers, pension funds, insurers
and advisers)".

From now on, products that do not take account of ESG
criteria will need to say so, while products promoting
environmental or social characteristics will need to say if they
are meeting their goals.

But so far in 2021, ESG investment performance has slowed
down compared to the previous year.

"The resurgence in value strategies, small caps and cyclical
industries have all been factors," Jefferies notes.

(Joice Alves)

*****

CHALLENGING TESLA IN THE STOCK MARKET (1058 GMT)

German carmakers' efforts to challenge the the world’s
leader in electric vehicles Tesla are starting to pay
off also in the stock market, it seems.

Deutsche Bank analysts recall that yesterday big tech stocks
did well despite rising interest rates, with retail favourites
still on the rise with one notable exception.

"One such favourite Tesla (-4.39%) was down on the day
though and it must be significant that VW's preferred shares
rose +6.71% on the company's plans of how they can beat Tesla to
be the world's leader in electric vehicles," they say.

Below the chart of Volkswagen (orange) and Tesla (blue)
stocks in the recent days.

It seems that retail investors have targeted Europe after
Volkswagen announced its ambitious plans on electrical driving.

BMW said today it expects at least half of its
sales to be zero emission vehicles by 2030, setting a more
conservative target than some rivals in the race to embrace
cleaner driving.

(Stefano Rebaudo)

*****

AUTOS STOCKS PROP UP THE STOXX 600 (0853 GMT)

European STOXX 600 index is just below the floating line
with autos stocks still on the rise after yesterday’s jump,
while commodities related stocks are in negative territory.

More good news is boosting the autos stock index,
which is up 1.4%, hitting a fresh two-year high.

Shares in BMW are up 4.4% after the company said
it expects a significant year-on-year increase in group pretax
profit in 2021.

Volkswagen’s ambitious expansion plans in electric driving
are also boosting the sector. Its shares are rising 2.3%.

Basic materials and oil and gas are among the
worst performers after their recent rally.

The STOXX 600 index is down 0.2%.

Financial markets across the globe are on hold ahead of the
Fed policy meeting outcome, which is expected to give clues
about next central bank’s moves on interest rates.

Eyes also on this week's first high-level, in-person contact
between Beijing and Washington since U.S. President Joe Biden
took office.

(Stefano Rebaudo)

*****

WHAT'S THE (DOT) PLOT, CHAIR POWELL? (0858 GMT)

It's Federal Reserve day and market focus is on the central
bank's rate-hike projections for 2023 in the so-called "dot
plot."

Some economists expect this to show the Fed now expects one
rate hike for 2023 versus none in December. An unchanged median
dot for 2023 could be interpreted as the Fed pushing back
against higher bond yields and markets' pricing of rate hikes.

The Fed will deliver its statement and economic forecasts at
1800 GMT, followed with a news briefing. Until then, barring
unforeseen events, markets will likely stay calm. Ten-year U.S.
yields are just off 13-month highs, the dollar index
is little changed and equity futures are a touch lower
.

The tone across world stocks is cautious too, with Asian
stocks tracking Wall Street's Tuesday fall and European markets
too set to open softer.

In the euro zone, it's the final day of voting in the Dutch
national election -- the first major general election in the EU
since the pandemic began.

Prime Minister Mark Rutte's VVD Party is expected to secure
a fourth term, but there is a risk markets are not adequately
pricing gains at the ballot for anti-establishment forces.

Some good news for AstraZeneca as Australia's
pharmaceutical regulator said the rollout of the company's
COVID-19 vaccine would continue, despite many European nations
pausing vaccinations to investigate reported side-effects.

The EU regulator will release findings on Thursday.

Elsewhere, Credit Agricole Italia has secured a
green light from European Central Bank supervisors for its
planned takeover bid of third-tier Italian lender Credito
Valtellinese .
Key developments that should provide more direction to markets
on Wednesday:

- Fed monetary policy decision and news conference.

- German, UK German new car registration data.

- US housing starts data due.

- Corporates: BMW said it expects a significant year-on-year
increase in pretax profit; Raiffeisen Bank aims to distribute
20%-50% of consolidated net profits; retail investment platform
Hargreaves Lansdown 2021 profit to beat expectations.

- Italy's biggest insurer Generali is studying an
acquisition in Russia worth nearly 2 billion euros ($2.4
billion), according to a media report.

(Dhara Ranasinghe)

*****

ON HOLD BEFORE THE FED (0628 GMT)

European stock futures are broadly unchanged along with
their U.S. peers as financial markets across the globe are on
hold before the U.S. Federal Reserve policy meeting outcome.

Investors are waiting for cues about central bank’s future
moves on interest rates after a jump in government bond yields
triggered by expectations of stronger than expected economic
growth and inflation.

Market will be closely watching also the first high-level
in-person contact between Beijing and Washington since U.S.
president Joe Biden took office. The meeting among Chinese and
U.S. officials will take place in Alaska on March 18 and 19.

(Stefano Rebaudo)

*****

More News
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more
9 Nov 2023 09:23

TOP NEWS: AstraZeneca ups guidance; inks licence deal for obesity drug

(Alliance News) - AstraZeneca PLC on Thursday announced that it signed a contract for an obesity drug as it reported a higher pretax profit in the third quarter of 2023, boosted by cancer drug conjugate Enhertu.

Read more
9 Nov 2023 08:57

LONDON MARKET OPEN: FTSE 100 kicks off day with cautious gain

(Alliance News) - London's FTSE 100 struggled for direction early Thursday, with a mixed slate of corporate updates, US interest rate worries and underwhelming China data preventing it from making more confident progress in early trade.

Read more
9 Nov 2023 07:48

LONDON BRIEFING: AstraZeneca ups outlook but S4 Capital cuts

(Alliance News) - London's FTSE 100 is set for another downbeat start to the day, with more hawkish comments from US central bankers and tepid data out of China doing little to lift the mood.

Read more
9 Nov 2023 07:18

AstraZeneca hikes guidance after strong third quarter

(Sharecast News) - AstraZeneca released its financial results for the third quarter and first nine months of 2023 on Thursday, hiking its full-year guidance on the back of a robust performance and momentum in several segments.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.